A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation

Targeting cancers with amplified or abnormally activated c-Met (hepatocyte growth factor receptor) may have therapeutic benefit based on nonclinical and emerging clinical findings. However, the eventual emergence of drug resistant tumors motivates the pre-emptive identification of potential mechanis...

詳細記述

保存先:
書誌詳細
主要な著者: Lee, Nathan V., Lira, Maruja E., Pavlicek, Adam, Ye, Jingjing, Buckman, Dana, Bagrodia, Shubha, Srinivasa, Sreesha P., Zhao, Yongjun, Aparicio, Samuel, Rejto, Paul A., Christensen, James G., Ching, Keith A.
フォーマット: Artigo
言語:Inglês
出版事項: Public Library of Science 2012
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3382171/
https://ncbi.nlm.nih.gov/pubmed/22745804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0039653
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料